EN
登录

Eurofins Viracor推出ExPeCT™抗CD19(obe-cel)CAR T细胞检测,以推进下一代免疫治疗中的主动监测

Eurofins Viracor Launches ExPeCT™ anti-CD19 (obe-cel) CAR T-Cell Assay to Advance Proactive Monitoring in Next-Generation Immunotherapy

PR Newswire 等信源发布 2026-03-26 22:00

可切换为仅中文


LENEXA, Kan.

堪萨斯州勒内克萨

,

March 26, 2026

2026年3月26日

/PRNewswire/ -- Eurofins Viracor, a leader in advanced clinical diagnostics, today announced the launch of the

/PRNewswire/ -- 欧陆科技集团旗下的维拉科公司(Eurofins Viracor),作为先进临床诊断领域的领导者,今天宣布推出

ExPeCT™ anti-CD19 (obe-cel) CAR T-cell assay

ExPeCT™ 抗CD19(obe-cel)CAR T细胞检测

, a cutting-edge solution designed to help clinicians monitor CAR T-cell therapy performance with validated precision and a quick turn-around-time for results.

,一种尖端解决方案,旨在帮助临床医生以经验证的精确度监测 CAR T 细胞疗法的性能,并快速获得结果。

The

The

ExPeCT™ brand of CAR T-cell assays

ExPeCT™品牌的CAR T细胞检测

enables clinicians to monitor CAR T-cell expansion and persistence in real time. This non-invasive blood test delivers results in approximately 24 hours after specimen receipt, potentially helping clinicians make timely therapy decisions.

使临床医生能够实时监测CAR T细胞的扩增和持久性。这种非侵入性的血液检测在收到样本后大约24小时内提供结果,可能帮助临床医生及时做出治疗决策。

The assay was developed exclusively to test the expansion and persistence of obecabtagene autoleucel (obe-cel) CAR T-cell's - a second-generation CAR T-cell therapy.

该检测方法专门用于测试第二代 CAR T 细胞疗法 obecabtagene autoleucel(obe-cel)的扩增和持久性。

For more information about the ExPeCT™ brand of assays and their applications, please visit

有关 ExPeCT™ 品牌检测方法及其应用的更多信息,请访问

https://www.eurofins-viracor.com/our-testing/immunology/

https://www.eurofins-viracor.com/our-testing/immunology/

or contact Client Services at (800) 305-5198.

或联系客户服务电话 (800) 305-5198。

About Eurofins Viracor

关于欧陆科技集团维拉科公司

With over 40 years of diagnostic expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Eurofins Viracor is passionate about delivering accurate, timely and actionable results, never losing sight of the connection between the testing it performs and the patients it serves..

拥有超过40年在传染病、免疫学和过敏测试方面的诊断经验,Eurofins Viracor致力于为免疫功能低下和重症患者提供准确、及时且可操作的结果,始终不忘其所进行的检测与所服务的患者之间的联系。

Eurofins Viracor is a subsidiary of Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit

Eurofins Viracor 是 Eurofins Scientific(EUFI.PA)的子公司,该公司是生物分析测试领域的全球领导者,也是基因组服务的世界领先者之一。欲了解更多信息,请访问

eurofins.com

欧陆科技集团.com

and

eurofins-viracor.com

欧陆科技-维拉科网站

.

About Eurofins – the global leader in bio-analysis

关于欧陆科技集团——生物分析领域的全球领导者

Eurofins is Testing for Life. The Eurofins Scientific SE network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services.

欧陆科技集团致力于生命检测。欧陆科技集团(Eurofins Scientific SE)的独立公司网络认为,其在食品、环境、药品和化妆品产品测试以及发现药理学、法医学、先进材料科学和农学合同研究服务领域是全球领导者。

It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialized and molecular clinical diagnostic testing and in-vitro diagnostic products..

它还是基因组学领域某些检测和实验室服务、临床研究支持以及生物制药合同开发和制造的市场领导者之一。在高度专业化和分子临床诊断测试及体外诊断产品方面,也拥有快速发展的业务 presence。

With over 65,000 staff across a network of more than 950 laboratories in over 1,000 companies in 59 countries, Eurofins offers a portfolio of over 200,000 analytical methods.

欧陆科技集团在59个国家的1000多家公司中拥有超过950个实验室,员工总数超过65,000人,提供超过200,000种分析方法的服务组合。

Eurofins Scientific SE shares are listed on Euronext Paris Stock Exchange.

欧陆科技集团的股票在巴黎泛欧证券交易所上市。

SOURCE Viracor Eurofins

来源 Viracor Eurofins

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示